posted on 2021-06-09, 15:33authored byCharles
G. Starr, Emily K. Makowski, Lina Wu, Brendan Berg, Jonathan S. Kingsbury, Yatin R. Gokarn, Peter M. Tessier
There is significant interest in
formulating antibody therapeutics
as concentrated liquid solutions, but early identification of developable
antibodies with optimal manufacturability, stability, and delivery
attributes remains challenging. Traditional methods of identifying
developable mAbs with low self-association in common antibody formulations
require relatively concentrated protein solutions (>1 mg/mL), and
this single challenge has frustrated early-stage and large-scale identification
of antibody candidates with drug-like colloidal properties. Here,
we describe charge-stabilized self-interaction nanoparticle spectroscopy
(CS-SINS), an affinity-capture nanoparticle assay that measures colloidal
self-interactions at ultradilute antibody concentrations (0.01 mg/mL),
and is predictive of antibody developability issues of high viscosity
and opalescence that manifest at four orders of magnitude higher concentrations
(>100 mg/mL). CS-SINS enables large-scale, high-throughput selection
of developable antibodies during early discovery.